Review of: "The Application and Pathway Regulation of Traditional Chinese Medicine in Lung Cancer Treatment: An Exploratory Review"

Maria Luisa Dupuis[1]

1 Istituto Superiore di Sanità

Potential competing interests: No potential competing interests to declare.

Thank you for the chance to review the manuscript. Here are my suggestions for improving the manuscript titled "Application and Pathway: Regulation of Traditional Chinese Medicine in Lung Cancer Treatment":

1. The manuscript contains instances of plagiarism, which should be addressed during the revision process. The first eleven lines contain plagiarism.

2. The statistical data needs proper referencing, as do the effects of resveratrol, artemisinin, Paris saponin II, triptolide, curcumin, and leonurin.

3. There is a discrepancy between the article's content and the sources cited.

References 1 and 5 to 10 do not align with the information presented.

Reference 30 pertains to Oridonin and its impact on inhibiting the migration and epithelial-to-mesenchymal transition of small-cell lung cancer cells.

References 31 to 37 are not relevant to the substance cited.

References 40 to 42 and 48 are not pertinent to the topic.

Reference 49 should be moved to sub-section 3.2.

References 50 to 53 are unrelated to the topic.

References 54 and 55 are not relevant to curcumin.

References 56 and 57 are not relevant to ginsenoside.

4. The author mentions the NF-κB signaling pathway is divided into three types - the classical pathway, the non-classical pathway, and other pathways. However, "other pathways" should be defined.

5. It is recommended to include a table that provides information about the role of traditional Chinese medicine in lung cancer to aid in better understanding.

6. Given that the paper discusses multi-drug resistance to anticancer drugs, a section dedicated to the mechanism of multidrug resistance can enhance the quality of the paper.

7. The mechanisms of action of specific substances have not been thoroughly examined. Additionally, the conclusion needs further attention.

8. I recommend considering the following articles to help improve the manuscript:

Zhicheng Wei, Jing Chen, Fang Zu, Julie Guo, Xiaodong Sun, Deming Liu, Conghai Liu. Traditional Chinese Medicine has great potential as candidate drugs for lung cancer: A review. Journal of Ethnopharmacology Volume 300, 10 January 2023, 115748.

Zhenglin He, Yihan Wang, Liang Han, Yue Hu, Xianling Cong. The mechanism and application of traditional Chinese medicine extracts in the treatment of lung cancer and other lung-related diseases. Review. Front Pharmacol. 2023 Dec 6:14:1330518.

Michael Yousef, Ioannis A. Vlachogiannis, Evangelia Tsiani. Effects of Resveratrol against Lung Cancer: In Vitro and In Vivo Studies. Nutrients 2017, 9(11), 1231.

Wangping Li, Chunmei Li, Lijie Ma, Faguang Jin. Resveratrol inhibits viability and induces apoptosis in the small-cell lung cancer H446 cell line via the PI3K/Akt/c-Myc pathway. Oncol Rep. 2020 Nov, 44(5): 1821–1830.

Waseem Raza, Suaib Luqman, Abha Meena. Prospects of tangeretin as a modulator of cancer targets/pathways. Pharmacological Research, Review. Volume 161, November 2020.

Li-Mei Wu, Xiao-Zhong Liao, Yan Zhang, Zi-Rui He, Shi-Qing Nie, Bin Ke, Lin Shi, Jian-Fu Zhao,and Wen-Hui Chen Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway front Cell Dev Biol 2021.